FLT3 and acute myeloid leukemia: Sorafenib is a multi-kinase inhibitor, which no prolonged EFS or OS when combined with standard chemotherapy for de novo FLT3-mutated adult AML [100,101].Promising activity of sorafenib was seen in pediatric AML.